Etiology of the Neonatal Hypoglycemias.
Beta cell
Hyperinsulinism
Insulin
Ketones
Neonate
Journal
Advances in pediatrics
ISSN: 1878-1926
Titre abrégé: Adv Pediatr
Pays: United States
ID NLM: 0370436
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
medline:
30
6
2024
pubmed:
30
6
2024
entrez:
29
6
2024
Statut:
ppublish
Résumé
To provide a more appropriate foundation for dealing with the problem of hypoglycemia in newborn infants, this article focuses on the mechanisms which underlie the various forms of neonatal hypoglycemia and discusses their implications for newborn care. Evidence indicates that all of the major forms of neonatal hypoglycemia are the result of hyperinsulinism due to dysregulation of pancreatic islet insulin secretion. Based on these observations, the authors propose that routine measurement of B-hydroxybutyrate should be considered an essential part of glucose monitoring in newborn infants.
Identifiants
pubmed: 38944478
pii: S0065-3101(24)00325-6
doi: 10.1016/j.yapd.2024.03.001
pii:
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-134Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure C.A. Stanley serves on the Data Safety Monitoring Board for Zealand Pharma clinical trials in hyperinsulinism. D.D. De Leon has received consulting fees from Zealand Pharma A/S, Crinetics Pharmaceuticals, Hanmi Pharmaceuticals, Eiger Pharma, Twist Biosciences, and Rhythm Pharmaceuticals. Diva D. De Leon has received research funding from Zealand Pharma A/S, Rezolute, Crinetics Pharmaceuticals, Hanmi Pharmaceuticals, Twist Biosciences, Eiger Pharma, and Ultragenyx, United States for studies not discussed in this article. D.D. De Leon and C.A. Stanley serve on the Scientific Advisory Board for Congenital Hyperinsulinism International.